(NAGE) Niagen Bioscience - Ratings and Ratios

Niagen Bioscience, Inc. (NASDAQ:NAGE) is a bioscience company specializing in the development of healthy aging products, leveraging its proprietary ingredient technologies to cater to a diverse customer base across various channels. The companys business is segmented into consumer products, ingredients, and analytical reference standards and services, allowing it to maintain a robust presence in the market.

The companys product portfolio includes finished dietary supplements containing its proprietary ingredients, NAD+ test kits for healthcare practitioners, and raw materials supplied to manufacturers of consumer products. Notably, Niagen Bioscience commercializes nicotinamide riboside, an NAD+ precursor, under the flagship brand NIAGEN, which is distributed through various channels, including its proprietary e-commerce platform TRUNIAGEN.com, Amazon, and specialty retailers.

With a strong foundation in research and development, Niagen Bioscience also offers phytochemical reference standards and other R&D services, further solidifying its position in the life sciences industry. The companys rebranding from ChromaDex Corporation to Niagen Bioscience, Inc. in March 2025 signifies its strategic focus on its core business.

Analyzing the , the stocks recent price action indicates a bullish trend, with the last price at $10.76, above its SMA20 and SMA50. The ATR of $0.50 suggests moderate volatility. Considering the , Niagen Biosciences market capitalization stands at $836.53M USD, with a P/E ratio of 59.00 and a forward P/E of 65.36, indicating high growth expectations. The companys RoE of 33.88% highlights its efficiency in generating profits from shareholder equity.

Forecasting the stocks performance, we can expect a continued upward trend, driven by the companys strong brand presence, diversified product portfolio, and robust R&D capabilities. With the stock currently trading near its 52-week high of $10.95, a potential target price could be $12.50, representing a 16% increase from the current price. However, investors should be cautious of the high P/E ratio and potential volatility, as indicated by the ATR. A strategic entry point could be around $9.50, near the SMA20, offering a more favorable risk-reward ratio.